Aperçu: G.M.
Bien
que les coûts pour le séquençage de l'exome en totalité WES et du génome en totalité WGS demeurent élevés, les réductions futures
des coûts de matériel et d'équipement et une compréhension accrue des
variantes nouvellement découvertes et des variantes de signification
inconnue devraient conduite à un plus grand intérêt.
Genet Med. 2017 May 4. doi: 10.1038/gim.2017.47.
A microcosting and cost-consequence analysis of clinical genomic testing strategies in autism spectrum disorder
Tsiplova K1, Zur RM1, Marshall CR2,3, Stavropoulos DJ3,4, Pereira SL5, Merico D5, Young EJ4, Sung WWL5, Scherer SW5,6, Ungar WJ1,7.
Author information
- 1
- Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada.
- 2
- Genome Diagnostics, Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada.
- 3
- Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
- 4
- Cytogenetics, Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada.
- 5
- The Centre for Applied Genomics and Program in Genetics and Genomic Biology, The Hospital for Sick Children, Toronto, Ontario, Canada.
- 6
- McLaughlin Centre and Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
- 7
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
Abstract
PurposeWhole-exome (WES) and whole-genome sequencing (WGS) increase the diagnostic yield in autism spectrum disorder
(ASD) compared to chromosomal microarray (CMA), but there have been no
comprehensive cost analyses. The objective was to perform such an
assessment of CMA, WES, and WGS and compare the incremental cost per
additional positive finding in hypothetical testing
scenarios.MethodsFive-year patient and program costs were estimated from
an institutional perspective. WES and WGS estimates were based on HiSeq
2500 with an additional WGS estimate for HiSeq X platforms. Parameter
uncertainty was assessed with probabilistic and deterministic
sensitivity analysis.ResultsThe cost per ASD sample was CAD$1,655 (95%
CI: 1,611; 1,699) for WES, CAD$2,851 (95% CI: 2,750; 2,956) for WGS on
HiSeq X, and CAD$5,519 (95% CI: 5,244; 5,785) on HiSeq 2500, compared to
CAD$744 (95% CI 714, 773) for CMA. The incremental cost was over
CAD$25,000 per additional positive finding if CMA was replaced by newer
technology.
Conclusion
While costs for WES and WGS remain high, future reductions in material and equipment costs, and increased understanding of newly discovered variants and variants of unknown significance will lead to improved value.GENETICS in MEDICINE advance online publication, 4 May 2017; doi:10.1038/gim.2017.47.
Conclusion
While costs for WES and WGS remain high, future reductions in material and equipment costs, and increased understanding of newly discovered variants and variants of unknown significance will lead to improved value.GENETICS in MEDICINE advance online publication, 4 May 2017; doi:10.1038/gim.2017.47.
- PMID: 28471434
- DOI: 10.1038/gim.2017.47